Optimizing Erwinase dosing for ALL patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study aims to find the best dose of Erwinase for children with ALL to reduce side effects like high ammonia levels. It focuses on how the drug is processed by the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer called ALL
- You are being treated with the drug Erwinase
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
This trial tests a treatment plan for people with a certain type of acute lymphoblastic leukemia (ALL) called B-lineage ALL. It aims to see how well the treatment works and how safe it is.
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.